Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have received a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $37.3333.

Several brokerages have recently commented on NBTX. Guggenheim increased their price target on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. UBS Group boosted their price objective on Nanobiotix from $3.50 to $30.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Leerink Partners upped their price objective on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th. HC Wainwright reaffirmed a “buy” rating on shares of Nanobiotix in a report on Monday, May 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st.

Nanobiotix Price Performance

Shares of NBTX stock opened at $38.80 on Wednesday. Nanobiotix has a 1-year low of $4.93 and a 1-year high of $57.14. The firm has a fifty day moving average of $39.34 and a two-hundred day moving average of $31.32.

Institutional Trading of Nanobiotix

Several institutional investors have recently added to or reduced their stakes in NBTX. Millennium Management LLC acquired a new stake in shares of Nanobiotix during the fourth quarter worth $390,000. Royal Bank of Canada boosted its holdings in shares of Nanobiotix by 2,000.0% in the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after buying an additional 2,500 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Nanobiotix in the 4th quarter valued at about $220,000. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.